Nasal cavity

Lyra Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, March 21, 2024
Research, LYRA, Common, Bronchitis, Disease, MF, New Drug Application, COVID-19, Patient, Smell, Network congestion, CRS, United, Nasal cavity, Pharmacotherapy, Investment, Clinical trial, Therapy, Safety, Sinusitis, ESS, FDA, Food, Pharmaceutical industry

WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.  

Key Points: 
  • WATERTOWN, Mass., March 21, 2024 (GLOBE NEWSWIRE) -- Lyra Therapeutics, Inc. (Nasdaq: LYRA) (“Lyra” or the “Company”), a clinical-stage biotechnology company developing long-acting, anti-inflammatory nasal inserts for the treatment of chronic rhinosinusitis (CRS), today reported its financial results for the fourth quarter and full year ended December 31, 2023 and provided a corporate update.
  • LYR-220, a larger insert, is designed for CRS patients whose nasal cavity is enlarged due to previous ESS.
  • Cash, cash equivalents and short-term investments were $102.8 million as of December 31, 2023, compared to $102.6 million as of September 30, 2023.
  • The Company recorded an impairment charge of $1.6 million related to long-lived assets for the year ended December 31, 2023.

XHANCE Approved by FDA as First and Only Medication Indicated for Treatment of Adults with Chronic Rhinosinusitis without Nasal Polyps

Retrieved on: 
Friday, March 15, 2024
Nosebleed, Research, Polyp (medicine), Vanderbilt University, Sciatica, Fluticasone, Education, Drainage, Disease, Incidence, Headache, Inflammation, Patient, Conditional sentence, Chronic obstructive pulmonary disease, Sinusitis, CRS, Standard of care, Quality of life, Migraine, Nasal cavity, Ear, ENT, Service, MPH, Nose, OPTN, FDA, Frustration, Food, Pharmaceutical industry

YARDLEY, Pa., March 15, 2024 (GLOBE NEWSWIRE) -- Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced the U.S. Food and Drug Administration (FDA) has approved XHANCE® (fluticasone propionate) nasal spray for the treatment of chronic rhinosinusitis without nasal polyps in patients 18 years of age and older.

Key Points: 
  • Chronic sinusitis (also called “chronic rhinosinusitis” or “CRS”) is one of the most common chronic diseases, affecting approximately 30 million adults in the United States.
  • Research shows that the disease impairs quality of life to a similar degree as other serious chronic conditions, such as chronic obstructive pulmonary disease, sciatica, or migraine.
  • Chronic sinusitis is also one of the most common diagnoses in adult outpatient medicine.
  • Chronic sinusitis is diagnosed in approximately 10 million outpatient visits, of which approximately 70% result in antibiotic prescriptions, and leads to more than 600,000 surgeries annually.

Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating Concussion

Retrieved on: 
Monday, March 18, 2024
Pharmaceutical, Health, Neurology, Clinical Trials, Depression, Metabolism, Brain, NCE, Acute stress disorder, Concussion, Veterans' affairs, Executive, Common, Inflammation, Patient, United States Congress, TBI, Foundation (nonprofit), Anxiety, CTE, University, Military personnel, Oxidative stress, Human, GMP, Nasal cavity, Traumatic brain injury, DSM-IV codes, Phase, Traffic, Swelling, FDA, Animal, Pentagon, Chronic traumatic encephalopathy, Phase II, Marcus Foundation, Medical device

Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.

Key Points: 
  • Oragenics’ lead drug candidate, ONP-002 is combined with its intranasal device intended for the treatment of mild Traumatic Brain Injury (TBI), aka concussion.
  • Dr. Kelly was also National Director of the Avalon Action Alliance TBI Programs for which the MIBH serves as the clinical coordinating center.
  • “I am excited to join Oragenics as its Chief Medical Officer at such an important and pivotal time in the drug development process.
  • Dr. Kelly has interacted with the FDA and clinical trials for brain injury throughout his esteemed career.

Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
Tuesday, March 5, 2024
Pharmaceutical, Health, Clinical Trials, Mental Health, CTE, Nasal administration, Active ingredient, Metabolism, IIA, Traumatic brain injury, Concussion, API, Nasal cavity, Animal, GMP, Common, Traffic, Safety, Patient, DSM-IV codes, Phase, Chronic traumatic encephalopathy, NCE, Brain, Pharmaceutical industry

The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.

Key Points: 
  • The drug candidate is expected to be combined with its novel intranasal device, for the treatment of mild Traumatic Brain Injury, aka concussion.
  • A 40-patient Phase I human study showed ONP-002 to be safe and well-tolerated.
  • Phase II patients will be recruited between the ages of 18-55 in the acute phase following concussion.
  • “Preclinical intranasal targeting of the brain has been shown to improve outcomes in animals and safety margin following concussion.

InventHelp Inventor Develops Product to Relieve a Cold and Mucus (RKH-555)

Retrieved on: 
Monday, February 19, 2024
Mucus, Nasal cavity, Head, Sale, Common, SWEAT, Multimedia, Suite, COLD

I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.

Key Points: 
  • I thought others could benefit from this process," said an inventor, from Rocky Mount, N.C., "so I invented the COLD SWEAT.
  • My design would help eliminate colds and sinus problems by breaking up mucus that is found in the sinus and chest cavities."
  • The patent-pending invention provides effective relief from a cold by breaking up mucus found in the sinus and chest cavities.
  • In doing so, it would emit moisture/heat into the nasal cavity and atop the chest in order to break up mucus associated with colds.

Oragenics, Inc. Preparing for Phase II Clinical Trials to Treat Concussion

Retrieved on: 
Monday, February 5, 2024
Mental Health, Health, Neurology, Clinical Trials, General Health, Pharmaceutical, NCE, Memory, Concussion, CTE, Chronic traumatic encephalopathy, Traumatic brain injury, Nasal administration, Patient, Safety, Diagnosis, Brain, Animal, DSM-IV codes, Nasal cavity, Phase, Traffic, Common, Pharmaceutical industry

Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.

Key Points: 
  • Oragenics has begun the final process of synthesizing and formulating the drug needed for its Phase II clinical trial.
  • We are excited to get the Phase II clinical trials underway,” commented Dr. James “Jim” Kelly, Neurologist and Executive Director of the Marcus Institute of Brain Health and an advisor on the planned phase II trial.
  • The drug has a large safety margin between dosages used in the animal toxicology program and those used in the Phase I study and planned for the upcoming Phase II clinical trial.
  • Post concussion syndrome is linked to long term disability and occurs in as high as 20% of concussed patients.

Silo Pharma Enters into Exclusive License Agreement with Medspray Pharma BV for Intranasal Technology used in SPC-15 Treatment for PTSD

Retrieved on: 
Tuesday, November 21, 2023
Research, Patient safety, Nose, SILO, Brain, Anxiety, PTSD, Post-traumatic stress disorder, Nasal cavity, Silicon, Therapy, Area studies, Argyreia nervosa, Pharmaceutical industry

ENGLEWOOD CLIFFS, NJ, Nov. 21, 2023 (GLOBE NEWSWIRE) -- Silo Pharma, Inc. (Nasdaq: SILO) (“Silo” or “the Company”), a developmental stage biopharmaceutical company focused on merging traditional therapeutics with psychedelic research, today announced a new exclusive license agreement with medical technology manufacturer Medspray Pharma BV for its proprietary patented soft mist nasal spray technology, the delivery mechanism selected for Silo’s intranasal therapeutic drug SPC-15.

Key Points: 
  • “We began a collaboration with Medspray earlier this year for feasibility studies evaluating its patented technology as a delivery mechanism for our intranasal therapeutic drug SPC-15.
  • Based on successful outcomes from these studies, we have selected Medspray’s Spray Technology for our formulation,” said Eric Weisblum, Chief Executive Officer of Silo Pharma.
  • “As part of our manufacturing and sales contract, we have obtained exclusive rights to its spray mist technology for use with multiple indications including post-traumatic stress disorder (PTSD) and anxiety, as well as Alzheimer’s disease and anorexia.
  • The drug dispersion through the nose to brain has been designed to optimize patient safety and therapeutic delivery.

Akita Biosciences Launches to Pioneer Novel Intranasal Therapies

Retrieved on: 
Tuesday, October 10, 2023
IID, Health, Hospital, Distinguishing, Bacteria, Nasal cavity, Therapy, GRAS, FDA, Cone Health Women's Hospital, Risk, Virus, Escherichia coli, Brigham and Women's Hospital, Harvard Medical School, Assistant, Nose, SARS-CoV-2, RSV, Research, Infection, Atmosphere, Pharmaceutical industry, Vaccine, Anesthesiology, Brigham, COLUMBUS, Profi

BOSTON and COLUMBUS, Ohio, Oct. 10, 2023 /PRNewswire/ -- Akita Biosciences, a biotechnology company focused on consumer health, is launching today with a mission to bring novel therapies to market. The company is developing pioneering science around the importance of the nasal cavity, both as a pathway for therapeutics and as a way to defend against illness. Akita Biosciences was founded based on research conducted at Brigham and Women's Hospital in Boston.

Key Points: 
  • BOSTON and COLUMBUS, Ohio, Oct. 10, 2023 /PRNewswire/ -- Akita Biosciences , a biotechnology company focused on consumer health, is launching today with a mission to bring novel therapies to market.
  • Akita Biosciences was founded based on research conducted at Brigham and Women's Hospital in Boston.
  • Based on this research, "Akita Biosciences developed a radically simple approach that works with the natural defenses in the nose," said Alex Revelos, CEO.
  • Building on the commercial launch of Profi, Akita Biosciences expects to continue developing biomaterials to support a wide range wellness, drug delivery, and therapeutic applications.

Hexainnoheal develops new home-use medical device 'Flexible PainQ'

Retrieved on: 
Tuesday, October 10, 2023
Pain, Multimedia, Low-level laser therapy, Nasal cavity, Cell, Rhinitis, Lighting, Flexible, Pain management, LED, Health, VCSEL, Medical imaging, Amazon

SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Home-use medical device manufacturer Hexainnoheal has been gaining recognition for its pain therapy products.

Key Points: 
  • SEOUL, South Korea, Oct. 10, 2023 /PRNewswire/ -- Home-use medical device manufacturer Hexainnoheal has been gaining recognition for its pain therapy products.
  • Established in 2019, Hexainnoheal has been developing and supplying personal medical devices to the market using Low-Level Lasers, LED lighting, and electric current.
  • PainQ, its representative device, is a home use healthcare device for pain therapy that can effectively manage pain by combining Low Level Lasers, LED lighting, and low-frequency stimulation functions.
  • Hexainnoheal has extensive global marketing plans for CobiQ to enter its oversea export target markets, particularly North America and Europe.

HDT Bio Receives $1 Million Award from BLUE KNIGHT™ Resident QuickFire Challenge in Support of Project NextGen

Retrieved on: 
Wednesday, October 4, 2023
Infection, ASPR, BLUE, Biomedical Advanced Research and Development Authority, Nasal cavity, Office of Inspector General, U.S. Department of Health and Human Services, HHS, SARS-CoV-2, Cancer, Anglo-Scandinavian, RNA, Epidemic, Development, Administration, Administration for Strategic Preparedness and Response, BARDA, Disease, Vaccine

Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate

Key Points: 
  • Award will fund the development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal RIG-I Agonist RNA SARS-CoV-2 antiviral candidate
    SEATTLE, Oct. 4, 2023 /PRNewswire/ -- HDT Bio Corp., a clinical-stage private company developing advanced RNA products to treat and prevent infectious diseases and cancer, today announced that it has received a $1 million award from the BLUE KNIGHT™ Resident QuickFire Challenge.
  • BLUE KNIGHT is a joint initiative between the Biomedical Advanced Research and Development Authority (BARDA), part of the Administration for Strategic Preparedness and Response (ASPR) at the U.S. Department of Health and Human Services (HHS), and Johnson & Johnson Innovation – JLABS (JLABS).
  • The award will be used to support further development of HDT-201, HDT Bio's thermo-stable and broad-spectrum intranasal small RIG-I Agonist RNA antiviral candidate to prevent infection and transmission of SARS-CoV-2.
  • "We are honored to be recognized as an awardee of the BLUE KNIGHT™ Resident QuickFire Challenge and welcome the opportunity to collaborate together with BARDA to increase preparedness against new and ongoing epidemics.